Discussion on the AQUARiUS and EXCAAPE studies- Thomas Keane

(Length of discussion ~ 13 minutes)

Thomas Keane, MD reviews three state of the art presentations from the 2017 European Society for Medical Oncology (ESMO) meeting.  

Dr. Keane highlights the AQUARiUS study presented by Antoine Thiery-Vuillemin who overviewed the initial results from this patient reported outcomes (PROs) study among men receiving either abiraterone + prednisone or enzalutamide. The second study reviewed is the EXCAAPE study, a  phase II clinical trial of Radium-223 activity in patients with mCRPC with asymptomatic progression while on abiraterone acetate or enzalutamide besides AR-V7 mutational status. 

Dr. Keane concludes his discussion with a review of the a presentation by Nicholas D. James on adding abiraterone acetate for patients with high-risk prostate cancer starting long-term ADT: Outcomes in non-metastatic patients from STAMPEDE.

Additional Content on Prostate Cancer coverage from ESMO 2017

Watch: Commentary by Thomas Keane: Cancer Highlights from ESMO 2017

ESMO 2017: Initial Results from AQUARiUS, a Prospective, Observational, Multi-Centre Phase IV Study Assessing Patient-Reported Outcomes in mCRPC Patients Treated with Abiraterone Acetate plus prednisone or Enzalutamide

ESMO 2017: A Phase II Clinical Trial of Radium-223 Activity in Patients with mCRPC with Asymptomatic Progression While on Abiraterone Acetate or Enzalutamide Besides AR-V7 Mutational Status (EXCAAPE)

ESMO 2017: Randomized phase III trial of ipatasertib vs. placebo, plus abiraterone and prednisone/prednisolone, in men with asymptomatic or mildly symptomatic previously untreated metastatic castrate-resistant prostate cancer (mCRPC)

ESMO 2017: Adding abiraterone for patients with high-risk prostate cancer (PCa) starting long-term ADT: Outcomes in non-metastatic (M0) patients from STAMPEDE



Biography:

Thomas E. Keane, MBBCh, FRCSI, FACS